VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Abbott Laboratories vs CSL Limited

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$195.3B
Gross margin (TTM)55.5%
Operating margin (TTM)18.2%
Net margin (TTM)14.7%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

CSL Limited

CSL · ASX

Market cap (USD)$74.4B
Gross margin (TTM)48.9%
Operating margin (TTM)23.3%
Net margin (TTM)14.9%
SectorHealthcare
IndustryBiotechnology
CountryAU
Data as of2026-01-02
Moat score
77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into CSL Limited's moat claims, evidence, and risks.

View CSL analysis

Comparison highlights

  • Moat score gap: CSL Limited leads (77 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); CSL Limited has 3 segments (71.7% in CSL Behring).
  • Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; CSL Limited has 7 across 3.

Primary market context

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

CSL Limited

CSL Behring

Market

Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases

Geography

Global

Customer

Hospitals, specialty pharmacies, physicians; payers and national health systems

Role

Vertically integrated biopharma (plasma collection -> fractionation/manufacturing -> commercial distribution)

Revenue share

71.7%

Side-by-side metrics

Abbott Laboratories
CSL Limited
Ticker / Exchange
ABT - New York Stock Exchange
CSL - ASX
Market cap (USD)
$195.3B
$74.4B
Gross margin (TTM)
55.5%
48.9%
Operating margin (TTM)
18.2%
23.3%
Net margin (TTM)
14.7%
14.9%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Biotechnology
HQ country
US
AU
Primary segment
Cardiovascular & Electrophysiology Devices
CSL Behring
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
64 / 100
77 / 100
Moat domains
Demand, Legal, Supply
Supply, Legal, Demand
Last update
2025-12-30
2026-01-02

Moat coverage

Shared moat types

Procurement InertiaGovernment Contracting Relationships

Abbott Laboratories strengths

Brand TrustInstalled Base ConsumablesData Workflow LockinCompliance AdvantageDistribution ControlScale Economies Unit CostTraining Org Change CostsIP Choke Point

CSL Limited strengths

Supply Chain ControlPhysical Network DensityOperational ExcellenceRegulated Standards PipeCapacity Moat

Segment mix

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

CSL Limited segments

Full profile >

CSL Behring

Oligopoly

71.7%

CSL Seqirus

Oligopoly

13.9%

CSL Vifor

Oligopoly

14.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.